A joint study on the Lynx1 protein has revealed that the protein competes with human nicotinic acetylcholine receptors for binding to amyloids, which are the main cause of Alzheimer’s development. In the future, the protein could be used in the development of new therapies or future combinations for the treatment of the disease. The results of the experiment were published in the Neurobiology of Aging journal.
from Dementia Big http://ift.tt/29wQWk7 via alcoholic dementia
http://ift.tt/29u1gIJ
No comments:
Post a Comment